Key result
This review discusses the mechanisms and appropriate use of current and emerging anticoagulant therapies to achieve the correct balance between thrombosis and bleeding during percutaneous interventions.
This review summarizes the mechanisms and appropriate use of current and emerging anticoagulant therapies during percutaneous interventions to balance thrombosis and bleeding risks.
May inform anticoagulant selection during PCI to balance thrombosis and bleeding; leaves open optimal use of emerging agents pending prospective data.
The proper use of anticoagulants is crucial for ensuring optimal patient outcomes post percutaneous interventions in the cardiac catheterization laboratory. Anticoagulant agents such as unfractionated heparin, a thrombin inhibitor; low-molecular weight heparins, predominantly Factor Xa inhibitors; fondaparinux, a Factor Xa inhibitor and bivalirudin, a direct thrombin inhibitor have been developed to target various steps in the coagulation cascade to prevent formation of thrombin. Optimal anticoagulation achieves the correct balance between thrombosis and bleeding and is related to optimal outcomes with minimal complications. This review will discuss the mechanisms and appropriate use of current and emerging anticoagulant therapies used during percutaneous interventions.
No takes yet. Share an insight, caveat, or question.
Bhatty et al. (2014) conducted a review in Patients undergoing percutaneous intervention. Anticoagulant therapies was evaluated. This review discusses the mechanisms and appropriate use of current and emerging anticoagulant therapies to achieve the correct balance between thrombosis and bleeding during percutaneous interventions.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: